These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8656254)

  • 21. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of metastatic breast cancer with paclitaxel and doxorubicin.
    Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BW; Ejlertsen B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):13-7. PubMed ID: 8643964
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan.
    Horiguchi J; Rai Y; Tamura K; Taki T; Hisamatsu K; Ito Y; Seriu T; Tajima T
    Anticancer Res; 2009 Feb; 29(2):625-30. PubMed ID: 19331212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.
    Belli L; LeChevalier T; Gottfried M; Adams D; Ruffie P; LeCesne A; Tete L; Pellae-Cosset B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):29-33. PubMed ID: 8643967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
    Giordano SH; Booser DJ; Murray JL; Ibrahim NK; Rahman ZU; Valero V; Theriault RL; Rosales MF; Rivera E; Frye D; Ewer M; Ordonez NG; Buzdar AU; Hortobagyi GN
    Clin Cancer Res; 2002 Nov; 8(11):3360-8. PubMed ID: 12429622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
    Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
    J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.
    Valero V; Jones SE; Von Hoff DD; Booser DJ; Mennel RG; Ravdin PM; Holmes FA; Rahman Z; Schottstaedt MW; Erban JK; Esparza-Guerra L; Earhart RH; Hortobagyi GN; Burris HA
    J Clin Oncol; 1998 Oct; 16(10):3362-8. PubMed ID: 9779713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
    Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
    J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.
    Seidman AD; Hochhauser D; Gollub M; Edelman B; Yao TJ; Hudis CA; Francis P; Fennelly D; Gilewski TA; Moynahan ME; Currie V; Baselga J; Tong W; O'Donaghue M; Salvaggio R; Auguste L; Spriggs D; Norton L
    J Clin Oncol; 1996 Jun; 14(6):1877-84. PubMed ID: 8656256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Full dose paclitaxel plus vinorelbine as salvage chemotherapy in anthracycline-resistant advanced breast cancer: a phase II study.
    Polyzos A; Tsavaris N; Kosmas C; Gogas H; Toufexi H; Kosmidis C; Markopoulos C; Giannopoulos A; Papadopoulos O; Stamatiadis D; Kouraklis G
    J Chemother; 2003 Dec; 15(6):607-12. PubMed ID: 14998089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
    Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P
    J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment.
    Ramos M; González-Ageitos A; Amenedo M; González-Quintas A; Gamazo JL; Togores P; Losada G; Almanza C; Romero C; Gómez-Martín C
    J Chemother; 2003 Apr; 15(2):192-7. PubMed ID: 12797398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized trial of 3-hour versus 24-hour infusion of high-dose paclitaxel in patients with metastatic or locally advanced breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26.
    Smith RE; Brown AM; Mamounas EP; Anderson SJ; Lembersky BC; Atkins JH; Shibata HR; Baez L; DeFusco PA; Davila E; Tipping SJ; Bearden JD; Thirlwell MP
    J Clin Oncol; 1999 Nov; 17(11):3403-11. PubMed ID: 10550134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of capecitabine and weekly paclitaxel in patients with metastatic breast cancer previously treated with every-3-week taxane therapy.
    Blum JL; Dees EC; Vukelja SJ; Amare M; Gill DP; McMahon RT; Ilegbodu D; Asmar L; O'Shaughnessy JA
    Clin Breast Cancer; 2007 Feb; 7(6):465-70. PubMed ID: 17386123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer.
    Wist EA; Sommer HH; Ostenstad B; Risberg T; Fjaestad K
    Acta Oncol; 2004; 43(1):11-4. PubMed ID: 15068314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
    Moon YW; Sohn JH; Choi HJ; Chang H; Park BW; Kim SI; Park S; Koo JS; Kim YT; Roh JK; Chung HC; Kim JH
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):425-31. PubMed ID: 20012956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer: a preliminary report.
    Akerley W; Sikov WM; Cummings F; Safran H; Strenger R; Marchant D
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-87-S17-90. PubMed ID: 9374102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Weekly paclitaxel therapy for metastatic breast cancer].
    Kokufu I; Taniguchi H; Kimura F; Fukuda K; Yamamoto M; Yano T; Yamada K
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):221-6. PubMed ID: 11865627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.